James Condulis

Stock Analyst at Stifel Nicolaus

(2.91)
# 2,761
Out of 4,983 analysts
59
Total ratings
46.9%
Success rate
4.3%
Average return

Stocks Rated by James Condulis

Braveheart Bio
Sep 9, 2026
Reiterated: Buy
Price Target: $45
Current: $27.71
Upside: +62.40%
NewAmsterdam Pharma Company
Sep 8, 2026
Reiterated: Buy
Price Target: $50
Current: $21.93
Upside: +128.00%
Arrowhead Pharmaceuticals
Aug 31, 2026
Reiterated: Buy
Price Target: $104
Current: $67.74
Upside: +53.53%
Amylyx Pharmaceuticals
Aug 18, 2026
Reiterated: Buy
Price Target: n/a
Current: $33.94
Upside: -
Aardvark Therapeutics
Aug 13, 2026
Reiterated: Hold
Price Target: $6
Current: $5.53
Upside: +8.50%
Edgewise Therapeutics
Aug 11, 2026
Reiterated: Hold
Price Target: $36
Current: $46.94
Upside: -23.31%
Cytokinetics
Aug 7, 2026
Reiterated: Buy
Price Target: $108
Current: $69.92
Upside: +54.46%
Tectonic Therapeutic
Aug 7, 2026
Reiterated: Buy
Price Target: $75
Current: $27.21
Upside: +175.63%
X4 Pharmaceuticals
Aug 7, 2026
Reiterated: Buy
Price Target: $10
Current: $3.50
Upside: +185.71%
Mirum Pharmaceuticals
Aug 6, 2026
Reiterated: Buy
Price Target: $136
Current: $98.82
Upside: +37.62%
Downgraded: Hold
Price Target: $25$3
Current: $3.77
Upside: -20.42%